| Peer-Reviewed

Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro

Received: 22 January 2021    Accepted: 30 January 2021    Published: 9 February 2021
Views:       Downloads:
Abstract

Background: Cardiovascular events (CVEs) have emerged as an important cause of morbimortality in people living with HIV/AIDS (PLHA). We aimed to investigate factors associated with incident CVE and compare the observed incidence with the predicted CVE risk by three different equations. Methods: Among the 649 active participants of the INI-ELSA cohort, we analysed data of 644 individuals free of CVE at baseline examinations. We used Cox regression models to study factors associated with CVE and to assess the equation's performance we compared the observed incidence with the overall 5-year predicted risks. Results: Over a median follow-up of 6.26-years (interquartile range [IQR] 6.01-6.47), there were 18 CVE, four deaths. Overall, 57.92% were male, median age was 43.4 years (35.82-50.73), most were on cART (88.65%). Participants who had CVE were older, had poorer renal function, higher proportion of dyslipidemia and higher levels of systolic blood pressure and triglycerides. The observed CVE rate was 2.90% (1.60-4.90%) whereas their overall cardiovascular disease (CVD) risk differed depending on which score was used: 0.91 (0.42-20), 1.16 (0.38-2.78) and 1.68 (0.60-3.87), according to Framingham, ASCVD and DAD, respectively. In the multivariable Cox analysis black race, smoking 10+ packs years, dyslipidemia, current CD4 cell count x101, cumulative viral load and time on NNRTI were independent predictors of CVE. Conclusion: Both traditional and HIV-related factors were associated with incident CVE. Risk scores were inconsistent in classifying patients who had CVE as high risk, indicating that validation studies are required to improve risk assessment of PLHA in Brazil.

Published in International Journal of Infectious Diseases and Therapy (Volume 6, Issue 1)
DOI 10.11648/j.ijidt.20210601.13
Page(s) 17-26
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Acquired Immunodeficiency Syndrome, Cardiovascular Disease, Risk Assessment

References
[1] K. So-Armah et al., "HIV and cardiovascular disease," The lancet. HIV, vol. 7, no. 4, pp. e279-e293, Apr 2020, doi: 10.1016/S2352-3018(20)30036-9.
[2] S. De Wit et al., "Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study," Diabetes care, vol. 31, no. 6, pp. 1224-9, Jun 2008, doi: 10.2337/dc07-2013.
[3] L. Galli et al., "Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy," European journal of epidemiology, vol. 27, no. 8, pp. 657-65, Aug 2012, doi: 10.1007/s10654-012-9707-5.
[4] D. Klein, L. B. Hurley, C. P. Quesenberry, Jr., and S. Sidney, "Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?," Journal of acquired immune deficiency syndromes, vol. 30, no. 5, pp. 471-7, Aug 15 2002, doi: 10.1097/00126334-200208150-00002.
[5] S. A. Riddler et al., "Impact of HIV infection and HAART on serum lipids in men," JAMA : the journal of the American Medical Association, vol. 289, no. 22, pp. 2978-82, Jun 11 2003, doi: 10.1001/jama.289.22.2978.
[6] G. M. Behrens, "Cardiovascular risk and body-fat abnormalities in HIV-infected adults," The New England journal of medicine, vol. 352, no. 16, pp. 1721-2; author reply 1721-2, Apr 21 2005, doi: 10.1056/NEJM200504213521620.
[7] A. Pawlos, M. Broncel, E. Wlazlowska, E. Jablonowska, and P. Gorzelak-Pabis, "Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations," PloS one, vol. 15, no. 12, p. e0244675, 2020, doi: 10.1371/journal.pone.0244675.
[8] M. S. Freiberg et al., "HIV infection and the risk of acute myocardial infarction," JAMA internal medicine, vol. 173, no. 8, pp. 614-22, Apr 22 2013, doi: 10.1001/jamainternmed.2013.3728.
[9] R. B. D'Agostino, Sr. et al., "General cardiovascular risk profile for use in primary care: the Framingham Heart Study," Circulation, vol. 117, no. 6, pp. 743-53, Feb 12 2008, doi: 10.1161/CIRCULATIONAHA.107.699579.
[10] R. B. D'Agostino, Sr., S. Grundy, L. M. Sullivan, P. Wilson, and C. H. D. R. P. Group, "Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation," JAMA : the journal of the American Medical Association, vol. 286, no. 2, pp. 180-7, Jul 11 2001, doi: 10.1001/jama.286.2.180.
[11] J. Marrugat et al., "An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas," Journal of epidemiology and community health, vol. 57, no. 8, pp. 634-8, Aug 2003, doi: 10.1136/jech.57.8.634.
[12] S. Herrera et al., "The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona," HIV clinical trials, vol. 17, no. 4, pp. 131-9, Jul 2016, doi: 10.1080/15284336.2016.1177266.
[13] L. F. d. S. Pinto Neto, F. R. Dias, F. F. Bressan, and C. R. O. Santos, "Comparison of the ACC/AHA and Framingham algorithms to assess cardiovascular risk in HIV-infected patients," Brazilian Journal of Infectious Diseases, vol. 21, pp. 577-580, 2017. [Online]. Available: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000600577&nrm=iso.
[14] Y. C. Chia, H. M. Lim, and S. M. Ching, "Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study," BMC cardiovascular disorders, vol. 14, p. 163, Nov 20 2014, doi: 10.1186/1471-2261-14-163.
[15] V. Estrada et al., "Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy," Revista clinica espanola, vol. 220, no. 3, pp. 149-154, Apr 2020, doi: 10.1016/j.rce.2019.05.006. Riesgo de enfermedad cardiovascular en pacientes con infeccion VIH en tratamiento antirretroviral.
[16] N. Friis-Moller et al., "An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D: A: D) study," European journal of preventive cardiology, vol. 23, no. 2, pp. 214-23, Jan 2016, doi: 10.1177/2047487315579291.
[17] P. Muntner et al., "Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations," JAMA : the journal of the American Medical Association, vol. 311, no. 14, pp. 1406-15, Apr 9 2014, doi: 10.1001/jama.2014.2630.
[18] C. M. Diaz et al., "Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study," BMC infectious diseases, vol. 16, p. 376, Aug 8 2016, doi: 10.1186/s12879-016-1735-4.
[19] B. Grinsztejn et al., "Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era," PloS one, vol. 8, no. 4, p. e59768, 2013, doi: 10.1371/journal.pone.0059768.
[20] D. Chor et al., "[Questionnaire development in ELSA-Brasil: challenges of a multidimensional instrument]," Revista de saude publica, vol. 47 Suppl 2, pp. 27-36, Jun 2013. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/24346718. Questionario do ELSA-Brasil: desafi os na elaboracao de instrumento multidimensional.
[21] P. A. Lotufo, "[Setting up the longitudinal study for adult health (ELSA-Brasil]," Revista de saude publica, vol. 47 Suppl 2, pp. 3-9, Jun 2013. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/24346715. Construcao do Estudo Longitudinal de Saude do Adulto (ELSA-Brasil).
[22] E. M. Aquino et al., "Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design," American journal of epidemiology, vol. 175, no. 4, pp. 315-24, Feb 15 2012, doi: 10.1093/aje/kwr294.
[23] M. I. Schmidt et al., "Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil)," International journal of epidemiology, vol. 44, no. 1, pp. 68-75, Feb 2015, doi: 10.1093/ije/dyu027.
[24] P. T. O'Gara et al., "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions," Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, vol. 82, no. 1, pp. E1-27, Jul 1 2013, doi: 10.1002/ccd.24776.
[25] C. Sociedade Brasileira de, "[Guidelines for Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction of the Brazilian Society of Cardiology (II Edition, 2007)]," Arquivos brasileiros de cardiologia, vol. 89, no. 4, pp. e89-131, Oct 2007, doi: 10.1590/s0066-782x2007001600015. Diretrizes (II Edicao, 2007) da Sociedade Brasileira de Cardiologia sobre angina instavel e infarto agudo do miocardio sem supradesnivel do segmento ST.
[26] C. P. Cannon et al., "2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards)," Circulation, vol. 127, no. 9, pp. 1052-89, Mar 5 2013, doi: 10.1161/CIR.0b013e3182831a11.
[27] A. R. Lifson et al., "Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials," HIV clinical trials, vol. 11, no. 4, pp. 205-19, Jul-Aug 2010, doi: 10.1310/hct1104-205.
[28] M. J. Radford et al., "ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America," Circulation, vol. 112, no. 12, pp. 1888-916, Sep 20 2005, doi: 10.1161/CIRCULATIONAHA.105.170073.
[29] J. M. Fria, R. C. Moreira. S. Wagner. R. Ismerio. S. Ribeiro. V. G. Veloso. B. Grinsztejn. A. G. Pacheco, "Validation of cardiovascular events in an HIV positive cohort HIV Evandro Chagas Institute," presented at the X Brazilian Congress of epidemiology, 2017.
[30] M. J. Mugavero et al., "Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy," Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 53, no. 9, pp. 927-35, Nov 2011, doi: 10.1093/cid/cir526.
[31] R. C. Team. ""R: A Language and Environment for Statistical Computing."." (accessed 2018).
[32] G. V. De Socio, G. Pucci, F. Baldelli, and G. Schillaci, "Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study," BMC infectious diseases, vol. 17, no. 1, p. 414, Jun 12 2017, doi: 10.1186/s12879-017-2510-x.
[33] E. Quiros-Roldan et al., "Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012," AIDS care, vol. 28, no. 12, pp. 1551-1558, Dec 2016, doi: 10.1080/09540121.2016.1198750.
[34] M. G. Buhnerkempe et al., "Prevalence of refractory hypertension in the United States from 1999 to 2014," Journal of hypertension, vol. 37, no. 9, pp. 1797-1804, Sep 2019, doi: 10.1097/HJH.0000000000002103.
[35] C. L. Jackson et al., "Black-white disparities in overweight and obesity trends by educational attainment in the United States, 1997-2008," Journal of obesity, vol. 2013, p. 140743, 2013, doi: 10.1155/2013/140743.
[36] M. C. Marshall, Jr., "Diabetes in African Americans," Postgraduate medical journal, vol. 81, no. 962, pp. 734-40, Dec 2005, doi: 10.1136/pgmj.2004.028274.
[37] I. S. Santos et al., "Carotid intima-media thickness value distributions in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)," Atherosclerosis, vol. 237, no. 1, pp. 227-35, Nov 2014, doi: 10.1016/j.atherosclerosis.2014.09.004.
[38] L. B. M. Machado et al., "Ideal cardiovascular health score at the ELSA-Brasil baseline and its association with sociodemographic characteristics," International journal of cardiology, vol. 254, pp. 333-337, Mar 1 2018, doi: 10.1016/j.ijcard.2017.12.037.
[39] P. M. Mendes et al., "Association between perceived racial discrimination and hypertension: findings from the ELSA-Brasil study," Cadernos de saude publica, vol. 34, no. 2, p. e00050317, Mar 1 2018, doi: 10.1590/0102-311X00050317.
[40] R. Desai et al., "Racial and sex disparities in resource utilization and outcomes of multi-vessel percutaneous coronary interventions (a 5-year nationwide evaluation in the United States)," Cardiovascular diagnosis and therapy, vol. 9, no. 1, pp. 18-29, Feb 2019, doi: 10.21037/cdt.2018.09.02.
[41] P. Schroff, C. M. Gamboa, R. W. Durant, A. Oikeh, J. S. Richman, and M. M. Safford, "Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study," Journal of the American Heart Association, vol. 6, no. 9, Aug 28 2017, doi: 10.1161/JAHA.116.005449.
[42] B. A. P. Phan et al., "Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis," Circulation. Cardiovascular imaging, vol. 10, no. 7, Jul 2017, doi: 10.1161/CIRCIMAGING.116.005995.
[43] P. Y. Hsue et al., "Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection," Circulation, vol. 109, no. 13, pp. 1603-8, Apr 6 2004, doi: 10.1161/01.CIR.0000124480.32233.8A.
[44] R. Mdodo et al., "Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys," Annals of internal medicine, vol. 162, no. 5, pp. 335-44, Mar 3 2015, doi: 10.7326/M14-0954.
[45] J. M. Tesoriero, S. M. Gieryic, A. Carrascal, and H. E. Lavigne, "Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation," AIDS and behavior, vol. 14, no. 4, pp. 824-35, Aug 2010, doi: 10.1007/s10461-008-9449-2.
[46] C. S. S. J. A. O’Halloran, P. WG Mallon, "Dyslipidemia, Atherosclerosis and Cardiovascular Disease: An Increasingly Important Triad in an Aging Population Living With HIV," Future virology, vol. 8, no. 10, pp. 1021-1034., 2013.
[47] A. J. Rodger et al., "Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population," Aids, vol. 27, no. 6, pp. 973-9, Mar 27 2013, doi: 10.1097/QAD.0b013e32835cae9c.
[48] R. M. Alvi et al., "Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center," American heart journal, vol. 210, pp. 39-48, Apr 2019, doi: 10.1016/j.ahj.2019.01.002.
[49] G. F. de Larranaga, A. Petroni, G. Deluchi, B. S. Alonso, and J. A. Benetucci, "Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients," Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol. 14, no. 1, pp. 15-8, Jan 2003, doi: 10.1097/01.mbc.0000046173.06450.40.
[50] G. Strategies for Management of Antiretroviral Therapy Study et al., "CD4+ count-guided interruption of antiretroviral treatment," The New England journal of medicine, vol. 355, no. 22, pp. 2283-96, Nov 30 2006, doi: 10.1056/NEJMoa062360.
[51] A. M. Thompson-Paul et al., "Cardiovascular Disease Risk Prediction in the HIV Outpatient Study," Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 63, no. 11, pp. 1508-1516, Dec 1 2016, doi: 10.1093/cid/ciw615.
[52] P. Raggi et al., "Prediction of hard cardiovascular events in HIV patients," The Journal of antimicrobial chemotherapy, vol. 71, no. 12, pp. 3515-3518, Dec 2016, doi: 10.1093/jac/dkw346.
[53] H. M. C. R. N. J. A. D. D. D. S. H. R. Y. M. J. F. R. M. M. S., "Comparing Cardiovascular Disease Risk Scores for Use in HIV-Infected Individuals. Optimal cardiovascular disease risk score for HIV " presented at the Conference on Retroviruses and Opportunistic Infections, Boston, 2016.
Cite This Article
  • APA Style

    Rodrigo Carvalho Moreira, Mariana Alencar Miranda, Jessica Muller, Sandra Wagner Cardoso, Ronaldo Ismerio Moreira, et al. (2021). Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro. International Journal of Infectious Diseases and Therapy, 6(1), 17-26. https://doi.org/10.11648/j.ijidt.20210601.13

    Copy | Download

    ACS Style

    Rodrigo Carvalho Moreira; Mariana Alencar Miranda; Jessica Muller; Sandra Wagner Cardoso; Ronaldo Ismerio Moreira, et al. Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro. Int. J. Infect. Dis. Ther. 2021, 6(1), 17-26. doi: 10.11648/j.ijidt.20210601.13

    Copy | Download

    AMA Style

    Rodrigo Carvalho Moreira, Mariana Alencar Miranda, Jessica Muller, Sandra Wagner Cardoso, Ronaldo Ismerio Moreira, et al. Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro. Int J Infect Dis Ther. 2021;6(1):17-26. doi: 10.11648/j.ijidt.20210601.13

    Copy | Download

  • @article{10.11648/j.ijidt.20210601.13,
      author = {Rodrigo Carvalho Moreira and Mariana Alencar Miranda and Jessica Muller and Sandra Wagner Cardoso and Ronaldo Ismerio Moreira and Estevao Nunes and Rosane Griep and Maria Jesus Fonseca and Valdilea Veloso and Beatriz Grinsztejn and Dora Chor and Antonio Guilherme Pacheco},
      title = {Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro},
      journal = {International Journal of Infectious Diseases and Therapy},
      volume = {6},
      number = {1},
      pages = {17-26},
      doi = {10.11648/j.ijidt.20210601.13},
      url = {https://doi.org/10.11648/j.ijidt.20210601.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijidt.20210601.13},
      abstract = {Background: Cardiovascular events (CVEs) have emerged as an important cause of morbimortality in people living with HIV/AIDS (PLHA). We aimed to investigate factors associated with incident CVE and compare the observed incidence with the predicted CVE risk by three different equations. Methods: Among the 649 active participants of the INI-ELSA cohort, we analysed data of 644 individuals free of CVE at baseline examinations. We used Cox regression models to study factors associated with CVE and to assess the equation's performance we compared the observed incidence with the overall 5-year predicted risks. Results: Over a median follow-up of 6.26-years (interquartile range [IQR] 6.01-6.47), there were 18 CVE, four deaths. Overall, 57.92% were male, median age was 43.4 years (35.82-50.73), most were on cART (88.65%). Participants who had CVE were older, had poorer renal function, higher proportion of dyslipidemia and higher levels of systolic blood pressure and triglycerides. The observed CVE rate was 2.90% (1.60-4.90%) whereas their overall cardiovascular disease (CVD) risk differed depending on which score was used: 0.91 (0.42-20), 1.16 (0.38-2.78) and 1.68 (0.60-3.87), according to Framingham, ASCVD and DAD, respectively. In the multivariable Cox analysis black race, smoking 10+ packs years, dyslipidemia, current CD4 cell count x101, cumulative viral load and time on NNRTI were independent predictors of CVE. Conclusion: Both traditional and HIV-related factors were associated with incident CVE. Risk scores were inconsistent in classifying patients who had CVE as high risk, indicating that validation studies are required to improve risk assessment of PLHA in Brazil.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Factors Associated with Incident Cardiovascular Events and Cardiac Risk Assessment in a Cohort of HIV-infected Participants in Rio de Janeiro
    AU  - Rodrigo Carvalho Moreira
    AU  - Mariana Alencar Miranda
    AU  - Jessica Muller
    AU  - Sandra Wagner Cardoso
    AU  - Ronaldo Ismerio Moreira
    AU  - Estevao Nunes
    AU  - Rosane Griep
    AU  - Maria Jesus Fonseca
    AU  - Valdilea Veloso
    AU  - Beatriz Grinsztejn
    AU  - Dora Chor
    AU  - Antonio Guilherme Pacheco
    Y1  - 2021/02/09
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijidt.20210601.13
    DO  - 10.11648/j.ijidt.20210601.13
    T2  - International Journal of Infectious Diseases and Therapy
    JF  - International Journal of Infectious Diseases and Therapy
    JO  - International Journal of Infectious Diseases and Therapy
    SP  - 17
    EP  - 26
    PB  - Science Publishing Group
    SN  - 2578-966X
    UR  - https://doi.org/10.11648/j.ijidt.20210601.13
    AB  - Background: Cardiovascular events (CVEs) have emerged as an important cause of morbimortality in people living with HIV/AIDS (PLHA). We aimed to investigate factors associated with incident CVE and compare the observed incidence with the predicted CVE risk by three different equations. Methods: Among the 649 active participants of the INI-ELSA cohort, we analysed data of 644 individuals free of CVE at baseline examinations. We used Cox regression models to study factors associated with CVE and to assess the equation's performance we compared the observed incidence with the overall 5-year predicted risks. Results: Over a median follow-up of 6.26-years (interquartile range [IQR] 6.01-6.47), there were 18 CVE, four deaths. Overall, 57.92% were male, median age was 43.4 years (35.82-50.73), most were on cART (88.65%). Participants who had CVE were older, had poorer renal function, higher proportion of dyslipidemia and higher levels of systolic blood pressure and triglycerides. The observed CVE rate was 2.90% (1.60-4.90%) whereas their overall cardiovascular disease (CVD) risk differed depending on which score was used: 0.91 (0.42-20), 1.16 (0.38-2.78) and 1.68 (0.60-3.87), according to Framingham, ASCVD and DAD, respectively. In the multivariable Cox analysis black race, smoking 10+ packs years, dyslipidemia, current CD4 cell count x101, cumulative viral load and time on NNRTI were independent predictors of CVE. Conclusion: Both traditional and HIV-related factors were associated with incident CVE. Risk scores were inconsistent in classifying patients who had CVE as high risk, indicating that validation studies are required to improve risk assessment of PLHA in Brazil.
    VL  - 6
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Oswaldo Cruz Foundation, Scientific Computing Program, Rio de Janeiro, Brazil

  • Internal Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  • Internal Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, Laboratory of Health and Environment Education, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, Department of Epidemiology and Quantitative Methods in Health, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, Department of Epidemiology and Quantitative Methods in Health, Rio de Janeiro, Brazil

  • Oswaldo Cruz Foundation, Scientific Computing Program, Rio de Janeiro, Brazil

  • Sections